spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Xeloda 

 HSMN NewsFeed - 11 Aug 2014
Mylan Launches Generic Xeloda(R) Tablets
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Significantly Extended Survival in People With Aggressive Form of Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Mar 2012
Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2012
Versant Ventures -- Leading Seed/Early Stage Healthcare Venture Capital Firm -- Appoints Dr. Guido Magni as Venture Partner
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2011
Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 May 2010
VIVUS Appoints Michael Miller to Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2010
Affymax Names John A. Orwin President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2010
GSK's TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Sep 2009
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Apr 2009
Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
Biopharmaceuticals Oncology Generics Litigation
 HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2008
Adherex Receives Orphan Drug Designation for ADH-1 in Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2008
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Xeloda(R) Combination Therapy in Esophagogastric Cancer Highlighted in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Sep 2007
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2007
Spectrum Strengthens Management With the Appointment of George Uy, an Industry Veteran, as Vice President, Marketing Oncology/Urology
Biopharmaceuticals Oncology Urology Personnel
 HSMN NewsFeed - 3 Jun 2007
Xeloda(R) Plus Avastin(R) Combination Delays Disease Progression in Women with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Biweekly Xeloda(R) Dosing Regimen is Well Tolerated in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2007
NCCN Updates Esophageal and Gastric Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2007
YM BioSciences Strengthens Program Management of Lead Drugs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2007
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2006
Landmark Tykerb(R) (Lapatinib) Data Published in the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit in Patients with Advanced Breast Cancer
Biopharmaceuticaals Oncology
 HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Patients With HER2-Positive Breast Cancer Significantly Benefit From Addition of Xeloda to Herceptin and Taxotere Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment Planned to Resume in AVANT International Phase III Trial in Adjuvant Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2006
Pharmion Announces Start of Phase 1 Trial Evaluating Satraplatin Plus Xeloda(R) in Patients With Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2006
Sirtex Announces Clinical Trial Evaluating the Use of SIR-Spheres(R) Microspheres with Xeloda(R) for Metastatic Liver Cancer
Devices Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 42

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 42 additional stories matching:
Xeloda
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.